Presented to:
Prof. Dr. Khalid Hussain Janbaz
Dean, Faculty of Pharmacy
B. Z. University Multan.

Presented by:

Irfan Ham...
Leukemia
Group of malignant disorders of the
hematopoietic tissues characteristically
associated with increased numbers of...
Development of Leukemia in the
Bloodstream

Stage 1- Normal

Stage 2- Symptoms

Stage 3- Diagnosis

Legend
White Cell

Red...
ALL
naïve
B-lymphocytes
Lymphoid
progenitor

Plasma
cells
T-lymphocytes

AML
Hematopoietic
stem cell

Myeloid
progenitor

...
Types of Leukemia
 Acute

Lymphoblastic Leukemia (ALL)

 Acute

Myeloblastic Leukemia

(AML)

 Chronic

Lymphocytic Leu...
Myeloid vs Lymphoid
 Any

disease that arises from the myeloid
elements (white cell, red cell, platelets) is a
myeloid di...
Acute vs. chronic leukemia
 Leukemias are classified
 Lymphoid cells



ALL - lymphoblasts
CLL – mature appearing lymph...
Chronic and Acute
Chronic Leukemia:
 accumulation of mature granulocytes or lymphocytes
 longer
 Progress
 Not

clinic...
Acute leukemias
Definition: Malignancies of immature
hematopoietic cells.
(> 20% blast cells in the bone marrow)
Types:

A...
Chronic Myeloid Leukaemia
 The

myeloproliferative diseases (MPDs)
are clonal stem cell disorders
characterised by leukoc...
Acute Lymphoblastic Leukemia
(ALL)
•

•
•

Clonal proliferation and accumulation
of blast cells in blood, bone marrow and
...
Bone Marrow Pathology
Acute Leukemia
 accumulation

of blasts in the marrow
Acute leukemias - laboratory
findings
. Blood examination
- anemia,
- thrombocytopenia,
- variable leukocyte count, usuall...
Acute leukemias - clinical
features
1.
2.
3.
4.
5.

6.
7.

Bleeding
Fever/infection
Bone/joint pain
Hepatomegaly
Splenomeg...
Acute leukemias - Laboratory
findings
1.
2.
3.
4.

Cytochemical stains
Immunophenotyping
Cytogenetics
Molecular studies
Differentiation between AML
and ALL


Age





Blood





AML - anemia, neutropenia, thrombocytopenia, myeloblasts ...
Acute Leukemia:
Clinical Manifestations
 Constitutional
 Weight

& Metabolic effects:

loss

 Fever
 Hyperkalemia

 H...
Acute Leukemia:
Clinical Manifestations
 Marrow

replacement, organ infiltration
& metabolic effects

 Marrow

replaceme...
Acute Leukemia:
Clinical Manifestations
 Organ

infiltration

 Bone

pain
 Hepatosplenomegaly
 Lymphadenopathy
 Gingi...
AML:
FAB classification
 French

American British classification

 M0-M7

based on morphology, and
special cytochemical ...
AML
FAB classification
 M0,M1,

M2: Myeloblasts with no, little or
some granulocytic maturation
 M3: Promyelocytic leuke...
AML – M1
 Note

the myeloblasts and the auer rod:
AML – M2
 Note

myeloblasts and hypogranulated
PMNs:
AML – M3
 Note

hypergranular promyelocytes:
AML – M4
 Note

monoblasts and promonocytes:
AML – M5A
 Note

monoblasts:
AML – M6
 Note

M1 type monoblasts
Morphologic subtypes of
acute lymphoblastic
leukemias (FAB
classification

Subtype
L1
L2
L3

Morphology
Occurrence (%)
Sma...
FAB Classification
L1
Small, uniform lymphoblasts
Scant cytoplasm, indistinct nucleoli,
occassional clefting of nucleus, c...
FAB Classification: L2
L2
Large, pleomorphic lymphoblasts
Abundant cytoplasm, predominant nucleoli,
nuclear clefting and i...
FAB Classification: L3
L3: Burkitt’s type
Uniform population of large lymphoblasts with
deeply basophilic cytoplasm, vacuo...
CHRONIC LEUKEMIAS
Definition:

Neoplastic proliferations of
mature haemopoeitic cells.

Types:

Chronic lymphocytic leukem...
CHRONIC LYMPHOCYTIC
LEUKAEMIA (CLL)



Neoplastic proliferations of mature
lymphocytes.
Distinguished from ALL by

A.
B....
SYMPTOMS of CLL
 Weakness, fatigue, vague sense of
being ill



Night sweat

 Infections esp pneumonia
TREATMENT OF CLL



Observation
Chemotherapy.

Oral chlorambucil
Fludarabine,

Immunotherapy
Anti-CD 20 (rituximab),

...
CHRONIC MYELOID
LEUKEMIA


CML is a clonal stem cell disorder
characterised by increased proliferation
of myeloid element...
CML is characterised by 3
distinct phases
a)

Chronic Phase:Proliferation of
myeloid cells, which show a full
range of mat...
CLINICAL PRESENTAITON OF
CML
Symptoms








Asymptomatic (50% of patients)

Fatigue
Weight loss
Abdominal fullness...
CYTOGENETICS OF CML
Philadelphia (Ph) chromosome is an

acquired cytogenetic abnormality in all
leukaemia cells in CML

...
Treatment
ACUTE LYMPHOBLASTIC

LEUKEMIA ( ALL)

DOSE

ROUTE REGIMEN

Induction ( 4 weeks)
Vincristin
Prednisolone
L- Asparaginase
Da...
(Treatment of acute
leukemias)Induction


Obtained by using high doses of chemotherapy

1 Severe bone marrow hypoplasia
2...
(Treatment of acute leukemia)
Consolidation
•

Different or same drugs to those used during
induction

•

Higher doses of ...
(Treatment of acute leukemias)
Maintenance
•

Smaller doses for longer period

•

Produce low neutrophil counts & platelet...
(Treatment of acute leukemias)
Supportive Care







Vascular access (Central line)
Prevention of vomiting
Blood pro...
ALL vs AML
ALL

AML

 Induction



Induction

 Consolidation



Consolidation

 Maintenance



No maintenance

 CNS...
DRUGS USED TO TREAT ACUTE
MELOBLASTIC LEUKEMIA ( AML)
 Anthracycline

Daunorubicin
Doxorubicin
Idarubicin
Mitoxantrone

...
DRUGS USED TO TREAT ACUTE
MYELOBLASTIC LEUKEMIA (
AML)


TOPOISOMERASE
INHIBITORS

ETOPOSIDE
TOPOTECAN
DNA DAMAGING
( ALK...
Treatment of Chronic
Lymphoblastic Leukemia (CLL)
 Alkylating

agents :
 Chlorambucil intermittently (10 mg/m2 x 7
days,...
Treatment of Chronic
Lymphoblastic Leukemia (CLL)









Corticosteroids :
Prednisolone : 30 mg / m2 for 3 weeks...
Nucleoside analogues
 Studies

have shown FLUDARABINE
superior to Chlorambucil in CLL with
higher clinical response rates...
Monoclonal Antibodies
 Alemtuzumab

( monoclonal antibody directed at

CD 52 ) :
 1st line agent
 For salvage in pts wi...
Monoclonal Antibodies







Anti-viral prophylaxis and prophylactic antibiotics for
Pneumocystis carnii are recommen...
Monoclonal Antibodies
 LENALIDOMIDE

: An immunomodulatory
drug currently approved for use in
Multiple Myeloma and MDS wi...
Bone Marrow Transplantation
 Allogenic

bone marrow transplantation is
the only known curative therapy.

 Addition

of A...
Radiotherapy






For many decades, irradiation of spleen was primary
treatment of CLL.
Useful in pts with bulky lymp...
Supportive therapy


Hypogammaglobulinemia : IV Immunoglobulins



Prednisolone - useful against autoimmune manifestatio...
CML-Principles of Treatment
 Control

& prolong chronic phase (non-curative)
- Tyrosine kinase inhibitors-Imatinib
- Alph...
TREATMENT OF CML
 Tyrosine kinase inhibitor (TKI) Imatinib (Glivec) is
the first line treatment
 In resistent cases 2nd ...
Bone marrow or PBSC
transplantation in leukemias

1.
2.









Types of transplant
Autologous transplant
Allogen...
THANK
YOU
 acute and chronic Leukemia  therapy by irfan hamid
 acute and chronic Leukemia  therapy by irfan hamid
 acute and chronic Leukemia  therapy by irfan hamid
 acute and chronic Leukemia  therapy by irfan hamid
 acute and chronic Leukemia  therapy by irfan hamid
 acute and chronic Leukemia  therapy by irfan hamid
Upcoming SlideShare
Loading in...5
×

acute and chronic Leukemia therapy by irfan hamid

1,235

Published on

its about treatment, sign, symptom and treatment of leukemia

Published in: Health & Medicine
0 Comments
7 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
1,235
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
154
Comments
0
Likes
7
Embeds 0
No embeds

No notes for slide

acute and chronic Leukemia therapy by irfan hamid

  1. 1. Presented to: Prof. Dr. Khalid Hussain Janbaz Dean, Faculty of Pharmacy B. Z. University Multan. Presented by: Irfan Hamid Ph.D. Pharmacology 2nd Semester Roll No. 05-PhDL-12 Acute & Chronic Leukemia Therapy
  2. 2. Leukemia Group of malignant disorders of the hematopoietic tissues characteristically associated with increased numbers of white cells in the bone marrow and / or peripheral blood
  3. 3. Development of Leukemia in the Bloodstream Stage 1- Normal Stage 2- Symptoms Stage 3- Diagnosis Legend White Cell Red Cell Platelet Blast Germ Stage 5a- Anemia Stage 4- Worsening Stage 5b- Infection
  4. 4. ALL naïve B-lymphocytes Lymphoid progenitor Plasma cells T-lymphocytes AML Hematopoietic stem cell Myeloid progenitor Neutrophils Eosinophils Basophils Monocytes Platelets Red cells
  5. 5. Types of Leukemia  Acute Lymphoblastic Leukemia (ALL)  Acute Myeloblastic Leukemia (AML)  Chronic Lymphocytic Leukemia (CLL)  Chronic Myelocytic Leukemia (CML)
  6. 6. Myeloid vs Lymphoid  Any disease that arises from the myeloid elements (white cell, red cell, platelets) is a myeloid disease ….. AML, CML  Any disease that arises from the lymphoid elements is a lymphoid disease ….. ALL, CLL
  7. 7. Acute vs. chronic leukemia  Leukemias are classified  Lymphoid cells  ALL - lymphoblasts CLL – mature appearing lymphocytes Myeloid cells AML – myeloblasts CML – mature appearing neutrophils  On a CBC, if you see:  Predominance of blasts   according to cell of origin: in blood consider an acute leukemia Leukocytosis with mature lymphocytosis consider CLL Leukocytosis with mature neutrophilia consider CML
  8. 8. Chronic and Acute Chronic Leukemia:  accumulation of mature granulocytes or lymphocytes  longer  Progress  Not clinical course (several to many years) slowly (runs a slow course) immediately fatal. Acute Leukemia:  excess  short clinical course (weeks to months)  Progress  Life myeloblasts or lymphoblasts rapidly (runs a fast course) expectancy short without treatment.
  9. 9. Acute leukemias Definition: Malignancies of immature hematopoietic cells. (> 20% blast cells in the bone marrow) Types: Acute Myeloid Leukemia (AML) Acute Lymphoblastic leukemia Groups: Childhood (< 15) Adult (> 15) (ALL) > 80% ALL > 80% AML
  10. 10. Chronic Myeloid Leukaemia  The myeloproliferative diseases (MPDs) are clonal stem cell disorders characterised by leukocytosis, thrombocytosis, erythrocytosis, splenomegaly, and bone marrow hypercelularity
  11. 11. Acute Lymphoblastic Leukemia (ALL) • • • Clonal proliferation and accumulation of blast cells in blood, bone marrow and other organs Disorder originates in single B or T lymphocyte progenitor Incidence in adults : 20% of acute leukemias
  12. 12. Bone Marrow Pathology
  13. 13. Acute Leukemia  accumulation of blasts in the marrow
  14. 14. Acute leukemias - laboratory findings . Blood examination - anemia, - thrombocytopenia, - variable leukocyte count, usually increased, - blood morphology: presence of blast cells 2. Bone marrow morphology - presence of blast cells, - suppression of normal haematopoiesis
  15. 15. Acute leukemias - clinical features 1. 2. 3. 4. 5. 6. 7. Bleeding Fever/infection Bone/joint pain Hepatomegaly Splenomegaly Lymphadenopathy CNS involvement
  16. 16. Acute leukemias - Laboratory findings 1. 2. 3. 4. Cytochemical stains Immunophenotyping Cytogenetics Molecular studies
  17. 17. Differentiation between AML and ALL  Age    Blood    AML - anemia, neutropenia, thrombocytopenia, myeloblasts and promyelocytes ALL - anemia, neutropenia, thrombocytopenia, lymphoblasts and prolymphocytes Morphology    AML - mainly in adults ALL - common in children AML - blasts are medium to large with more cytoplasm which may contain granules, Auer rods, fine nuclear chromatin, distinct nucleoli ALL - blasts are small to medium with scarce cytoplasm, no granules, fine nuclear chromatin and indistinct nucleoli Cytochemistry   AML - positive peroxidase and Sudan black, negative TdT ALL - negative peroxidase and Sudan black, positive TdT
  18. 18. Acute Leukemia: Clinical Manifestations  Constitutional  Weight & Metabolic effects: loss  Fever  Hyperkalemia  Hyperuricemia
  19. 19. Acute Leukemia: Clinical Manifestations  Marrow replacement, organ infiltration & metabolic effects  Marrow replacement  Neutropenia: infection  Anemia: pallor, fatigue, dyspnea  Thrombocytopenia: abnormal bruising and bleeding
  20. 20. Acute Leukemia: Clinical Manifestations  Organ infiltration  Bone pain  Hepatosplenomegaly  Lymphadenopathy  Gingival hypertrophy  Leukemic meningitis
  21. 21. AML: FAB classification  French American British classification  M0-M7 based on morphology, and special cytochemical studies  Historically, distinguishing AML M0 from ALL was a major clinical problem
  22. 22. AML FAB classification  M0,M1, M2: Myeloblasts with no, little or some granulocytic maturation  M3: Promyelocytic leukemia  M4: Myelomonocytic or eosinophilic  M5: Monocytic  M6: Erythroleukemia  M7: Megakaryoblastic Not all that useful except for M3
  23. 23. AML – M1  Note the myeloblasts and the auer rod:
  24. 24. AML – M2  Note myeloblasts and hypogranulated PMNs:
  25. 25. AML – M3  Note hypergranular promyelocytes:
  26. 26. AML – M4  Note monoblasts and promonocytes:
  27. 27. AML – M5A  Note monoblasts:
  28. 28. AML – M6  Note M1 type monoblasts
  29. 29. Morphologic subtypes of acute lymphoblastic leukemias (FAB classification Subtype L1 L2 L3 Morphology Occurrence (%) Small round blasts 75 clumped chromatin Pleomorphic larger blasts 20 clefted nuclei, fine chromatin Large blasts, nucleoli, 05 vacuolated cytoplasm
  30. 30. FAB Classification L1 Small, uniform lymphoblasts Scant cytoplasm, indistinct nucleoli, occassional clefting of nucleus, chromatin is clumped Affects primarily children
  31. 31. FAB Classification: L2 L2 Large, pleomorphic lymphoblasts Abundant cytoplasm, predominant nucleoli, nuclear clefting and indentation Affects adults
  32. 32. FAB Classification: L3 L3: Burkitt’s type Uniform population of large lymphoblasts with deeply basophilic cytoplasm, vacuoles, round to oval nuclei without indentation Affects adults and children
  33. 33. CHRONIC LEUKEMIAS Definition: Neoplastic proliferations of mature haemopoeitic cells. Types: Chronic lymphocytic leukemia (CLL) Chronic myeloid leukemia (CML)
  34. 34. CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)   Neoplastic proliferations of mature lymphocytes. Distinguished from ALL by A. B. C. D. Morphology of cells. Degree of maturation of cells. Immunologically immature blasts in ALL. CLL affects mainly elderly.
  35. 35. SYMPTOMS of CLL  Weakness, fatigue, vague sense of being ill  Night sweat  Infections esp pneumonia
  36. 36. TREATMENT OF CLL   Observation Chemotherapy. Oral chlorambucil Fludarabine,  Immunotherapy Anti-CD 20 (rituximab),  Anti-CD 52 (Alemtuzumab) Indications for starting chemotherapy a. Progressive Symptoms b. Progressive Anemia or Thrombocytopenia c. Bulky LN, large spleen d. Recurrent Infections
  37. 37. CHRONIC MYELOID LEUKEMIA  CML is a clonal stem cell disorder characterised by increased proliferation of myeloid elements at all stages of differentiation.  Incidence increases with age, M > F.
  38. 38. CML is characterised by 3 distinct phases a) Chronic Phase:Proliferation of myeloid cells, which show a full range of maturation. b) Accelerated Phase decrease in myeloid differentiation occurs. c) Blast crisis (acute leukemia)
  39. 39. CLINICAL PRESENTAITON OF CML Symptoms       Asymptomatic (50% of patients) Fatigue Weight loss Abdominal fullness and anorexia Abdominal pain, esp splenic area Increased sweating Easy bruising or bleeding
  40. 40. CYTOGENETICS OF CML Philadelphia (Ph) chromosome is an acquired cytogenetic abnormality in all leukaemia cells in CML  Reciprocal translocation of chromosomal material between chromosome 22 and chromosome 9. t(9;22)
  41. 41. Treatment
  42. 42. ACUTE LYMPHOBLASTIC LEUKEMIA ( ALL) DOSE ROUTE REGIMEN Induction ( 4 weeks) Vincristin Prednisolone L- Asparaginase Daunorubicin 1.5 mg/m2 40mg/m2 6000u/m2 45mg/m2 I.V Oral I.M I.V Weekly for 4 weeks Daily for 4 weeks 3xWeekly for 3 weeks Daily for 2 days Intensification(1 week) Vincristin Daunorubicin Prednisolone Etoposide Cytarabine Thioguanine 1.5mg/m2 45mg/m2 40mg/m2 100mg/m2 100mg/m2 80mg/m2 I.V I.V Oral I.V I.V Oral 1 dose Daily for 2 days Daily for 5 days Daily for 5 days 2x daily for 5 days Daily for 5 days CNS Prophylaxis( 3 weeks) Cranial irradiation Methotrexate 24 Gy I.T weekly for 3 weeks Oral Oral Oral I.V Weekly Daily 5days/ Month Monthly Maintenance Therapy ( 2 years) Methotrexate 6-Mercaptopurine Prednisolone vincristine 20mg/m2 75mg/m2 40mg/m2 1.5mg/m2
  43. 43. (Treatment of acute leukemias)Induction  Obtained by using high doses of chemotherapy 1 Severe bone marrow hypoplasia 2 Allowing regrowth of normal residual stem cells to regrow faster than leukemic cells.  Remission    Normal neutrophil count Normal platelet count Normal hemoglobin level Remission defined as < 5% blast in the bone marrow
  44. 44. (Treatment of acute leukemia) Consolidation • Different or same drugs to those used during induction • Higher doses of chemotherapy • Advantage: Delays relapse and survival improved
  45. 45. (Treatment of acute leukemias) Maintenance • Smaller doses for longer period • Produce low neutrophil counts & platelet counts • Objective is to eradicate progressively any remaining leukemic cells.
  46. 46. (Treatment of acute leukemias) Supportive Care      Vascular access (Central line) Prevention of vomiting Blood products (Anemia, ↓Plat) Prevention & treatment of infections (antibiotics) Management of metabolic complications
  47. 47. ALL vs AML ALL AML  Induction  Induction  Consolidation  Consolidation  Maintenance  No maintenance  CNS prophylaxis all  CNS – Selected group only patients
  48. 48. DRUGS USED TO TREAT ACUTE MELOBLASTIC LEUKEMIA ( AML)  Anthracycline Daunorubicin Doxorubicin Idarubicin Mitoxantrone  Antimetabolite Cladribine Cytarabine Fludarabine Hydroxyurea Methotrexate 6-Mercaptopurine 6-Thioguanine
  49. 49. DRUGS USED TO TREAT ACUTE MYELOBLASTIC LEUKEMIA ( AML)  TOPOISOMERASE INHIBITORS ETOPOSIDE TOPOTECAN DNA DAMAGING ( ALKYLATING AGENT) o CYCLOPHOSPHAMIDE CARBOPLATIN TEMOZOLOMIDE  CELL MATURING AGENT ALL-TRANS RETIONIC ACID (ATRA) ARSENIC TRIOXIDE o HYPOMETHYLATING AGENT AZACITIDINE DECITABINE
  50. 50. Treatment of Chronic Lymphoblastic Leukemia (CLL)  Alkylating agents :  Chlorambucil intermittently (10 mg/m2 x 7 days, monthly ) or continously ( 5 -10 mg / day )  Combinations :  COP : Cyclophosphamide, Oncovin, Prednisolone( 5 day – monthly course )  Chlorambucil + Epirubicin  CHOP : COP + Doxorubicin
  51. 51. Treatment of Chronic Lymphoblastic Leukemia (CLL)         Corticosteroids : Prednisolone : 30 mg / m2 for 3 weeks + 1 week tailing off for initial treatment of pts with Stage C disease. High – dose Methylprednisolone IV at 1 g/m2 ( 5-day monthly course ) Nucleoside analogues : Fludarabine ( 25 mg / m2 IV daily as 30 min infusion for 5 days every 28 days ) Fludarabine + Cyclophosphamide Pentostatin ( 2 mg/m2/day IV for 5 days every 28 days) Cladribine ( IV infusion over 2 hrs dose of 0.12 mg/kg/day for 5 consecutive days )
  52. 52. Nucleoside analogues  Studies have shown FLUDARABINE superior to Chlorambucil in CLL with higher clinical response rates, superior time to treatment failure, better tolerance in pts > 65 yrs.  FLUDARABINE – Currently 1st line of treatment in CLL
  53. 53. Monoclonal Antibodies  Alemtuzumab ( monoclonal antibody directed at CD 52 ) :  1st line agent  For salvage in pts with fludarabine refractory disease  Effective in CLL with p53 mutations  Very effective in clearing Bone Marrow disease  Limited activity in clearing bulky lymphadenopathy  Has role in consolidation therapy for elimination of minimal residual disease.
  54. 54. Monoclonal Antibodies      Anti-viral prophylaxis and prophylactic antibiotics for Pneumocystis carnii are recommended for pts receiving Alemtuzumab and for 2 – 4 months after treatment Rituximab – (monoclonal antibody specific for CD 20) used extensively in combination with chemotherapy. Fludarabine combined with Rituximab – shown higher clinical remission rates than fludarabine alone . FCR – ( Fludarabine, Cyclophosphamide, Rituximab ) – shown clinical response rates of 76% in trials. CFAR – ( Cyclophosphamide, Fludarabine, Alemtuzumab, Rituximab ) still under trials
  55. 55. Monoclonal Antibodies  LENALIDOMIDE : An immunomodulatory drug currently approved for use in Multiple Myeloma and MDS with deletion of Chr 5q .  Studies have shown response rates of 47 – 38 % with complete response rates of 9 % and elimination MRD have been reported.
  56. 56. Bone Marrow Transplantation  Allogenic bone marrow transplantation is the only known curative therapy.  Addition of ALEMTUZUMAB to pts receiving hematopoetic stem cell transplantation aids in elimination of MRD ( Minimal Residual Disease )
  57. 57. Radiotherapy     For many decades, irradiation of spleen was primary treatment of CLL. Useful in pts with bulky lymph nodes compressing nerves / other organs & massive / painful splenomegaly. IRRADIATION of mediastinum, extracorporeal irradiation of blood and total body irradiation – may reduce the peripheral blood lymphocyte counts and size of lymph node, spleen and liver. Total body irradiation plus cyclophosphamide & prednisolone had higher response to those treated with TBI alone.
  58. 58. Supportive therapy  Hypogammaglobulinemia : IV Immunoglobulins  Prednisolone - useful against autoimmune manifestations of disease.  Rituximab alone / in combination : effective in eliminating the B cell clone inducing autoimmune disorders, particularly autoimmune thrombocytopenia  Leukapheresis : removal of leukemic cells reduces tumor load and leukostasis.  Long term antibiotics
  59. 59. CML-Principles of Treatment  Control & prolong chronic phase (non-curative) - Tyrosine kinase inhibitors-Imatinib - Alpha-Interferon - Oral chemotherapy (Hydroxyurea)  Eradicate malignant Clone (curative) - Allogeneic BM/stem cell transplantation - Alpha Interferon - Imatinib? 2nd line TKIs
  60. 60. TREATMENT OF CML  Tyrosine kinase inhibitor (TKI) Imatinib (Glivec) is the first line treatment  In resistent cases 2nd line TKIs (Nilotinib, Dasatinib, Bosutinib) very useful  Allogenic bone marrow trasnsplantation can be curative in pts resisrant to TKIs but has significant complications & mortality  Accelerated and blast phase  Treat like AML or ALL followed by BMT
  61. 61. Bone marrow or PBSC transplantation in leukemias  1. 2.        Types of transplant Autologous transplant Allogeneic Transplant Purpose of transplant Autologous -To deliver a high dose of chemo to kill any residual cancer (lymphoma, multiple myeloma) Allogeneic -To eradicate residual leukemia cells -Graft vs leukemia effect
  62. 62. THANK YOU
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×